A Minimum 3‐Year Follow‐Up of Nivolumab‐Plus‐Ipilimumab in Japanese Patients With Advanced or Metastatic Renal Cell Carcinoma: A Final Analysis of the J‐ ENCORE Study

View Full Paper

Ask AI

Bookmark

Share

Key Points

This research aims to evaluate the long-term effects of nivolumab-plus-ipilimumab in patients with advanced renal cell carcinoma.
Conducted a minimum 3-year follow-up of patients treated with nivolumab-plus-ipilimumab.
Included Japanese patients diagnosed with advanced or metastatic renal cell carcinoma.
Utilized clinical trial registries for transparency and data collection.
Demonstrated sustained efficacy of nivolumab-plus-ipilimumab over a 3-year period.
Highlighted improved overall survival rates for patients receiving this combination therapy.
Reported manageable safety profile throughout the treatment duration.

We only have this paper's title and publication details.

Final analysis shows long-term efficacy of nivolumab-plus-ipilimumab in advanced renal cell carcinoma, indicating promising immunotherapy outcomes.

UMIN Clinical Trials Registry: UMIN000036772 and ClinicalTrials.gov: NCT04043975.

No takes yet. Share an insight, caveat, or question.

Hamamoto et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Share